Post-Brexit immigration – time for life sciences to prepare

25 October 2018
kerry_garcia_nyasha_gardner_large

Kerry Garcia (pictured above, left) and Nyasha Gardner, UK-based immigration specialists at law firm Stevens & Bolton, provide an Expert View on what the recently published Migration Advisory Committee (MAC) report on immigration means for businesses in the life sciences sector.

In September, the Migration Advisory Committee (MAC) published its long-awaited report on the impact on the UK labor market of the UK’s exit from the European Union (EU).

The MAC had been commissioned by the government to assess the impact of European Economic Area (EEA) migration on the UK’s economy and society, and to consider recommendations for the UK’s post-Brexit immigration system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical